Rakuten Medical

CA - San DiegoBiotechnology3 H-1B visas (FY2023)

Focus: Rakuten Medical is a San Diego-based biotech focused on antibody conjugates and photoimmunotherapy for oncology, particularly head and neck cancers. The company operates as a mid-cap biotech with a specialized, focused pipeline.

Oncology

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Open Jobs

4+2 this month

Stable — net +2 jobs in 30d

2 added, 0 removed. Backfill posture.

Should You Work at Rakuten Medical?

AI assessment

Rakuten Medical offers exposure to novel oncology science and Phase 3 catalysts, but limited hiring and opaque financials present career risk for those seeking growth runway or long-term stability.

Why Work Here

Cutting-edge modality focus: photoimmunotherapy (PIT) and antibody conjugates represent differentiated oncology approaches with less crowded competitive space than checkpoint inhibitors

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RM-1995

Cutaneous Squamous Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT05220748RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Phase 1

Help build intelligence for Rakuten Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Phase 3 programs in clinical development: ASP-1929 has advanced to Phase 3 for recurrent head and neck cancer, indicating potential near-term regulatory catalysts

100% H1B approval rate in 2023 (3 approvals, 0 denials) suggests strong visa sponsorship support for international talent

Watch Out For

Extremely limited hiring activity: only 2 active job openings and minimal recent recruitment signals indicate slow growth or resource constraints
Early-stage pipeline maturity: only 2 Phase 3 programs among 8 total trials; no approved products mean no revenue base and higher execution risk
No published data on financials, funding, employee count, or recent news limits visibility into company health and career trajectory stability

Generated by Claude from Rakuten Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2

Recurrent Head and Neck Cancer

Phase 1/2

Clinical Trials (1)

NCT02422979Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

Phase 1/2

200 mg Pembrolizumab

Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1/2

Clinical Trials (1)

NCT04305795An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Phase 1/2

ASP-1929 Photoimmunotherapy

Head and Neck Cancer

Phase 2

Clinical Trials (1)

NCT05265013ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Phase 2

ASP-1929 Photoimmunotherapy

Head and Neck Cancer

Phase 2

Clinical Trials (1)

NCT05182866ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Phase 2

Biospecimen Collection

Lung Non-Small Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT06943664Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Phase 2

ASP-1929 Photoimmunotherapy

Head and Neck Cancer

Phase 3

Clinical Trials (1)

NCT03769506ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Phase 3

ASP-1929 Photoimmunotherapy

Recurrent Head and Neck Squamous Cell Carcinoma

Phase 3

Clinical Trials (1)

NCT06699212A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Phase 3

Interview Prep Quick Facts

Founded: 2010

Portfolio: 8 clinical trials

Top TAs: Oncology

H-1B (2023): 3 approvals

Open Roles: 4 active jobs

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Rakuten Medical

Should You Work at Rakuten Medical?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (4)

Manager, Technical Operations and Supply Chain Management

Manager/Sr. Manager, Clinical GCP Quality Assurance

Medical Director

Director/Senior Director of Global Regulatory Affairs

Hiring Trend

Visa Sponsorship